Javascript is not enabled.

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.

Skip to content
Content starts here
Leaving Website

You are now leaving and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.

Recall Expanded for Common Heartburn Medication Zantac

Over-the-counter treatment may contain carcinogen, authorities say

spinner image Boxes of heartburn medication Zantac on a store shelf
Amy Lee/Alamy Stock Photo

The popular over-the-counter heartburn medication Zantac has been voluntarily recalled by its manufacturer, Sanofi, because of U.S. Food and Drug Administration warnings that it contains a potentially cancer-causing impurity.

Last month the FDA alerted the public to the existence of low levels of the carcinogen, N-nitrosodimethylamine, or NDMA, in heartburn drugs known as ranitidine medications (in a class of drugs called H2 blockers), including those under the Zantac brand.

spinner image Image Alt Attribute

AARP Membership

Join AARP for $12 for your first year when you sign up for Automatic Renewal. Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP The Magazine

Join Now

The news caused Walmart, CVS Pharmacy and Walgreens to halt sales of ranitidine drugs, which are now being tested for their potential risks. (The presence of NDMA in certain forms of the high blood pressure medication valsartan is also under FDA scrutiny.)

The FDA has not demanded a recall of Zantac, used widely to treat heartburn and ulcers by lowering acid production in the stomach, and suggests that those who want to stop taking prescription Zantac should first discuss other options with their doctors.

For expert tips to help feel your best, get AARP’s monthly Health newsletter.

"Although NDMA may cause harm in large amounts, the levels the FDA is finding in ranitidine from preliminary tests barely exceed amounts you might expect to find in common foods,” the agency said in its September alert.

Now Zantac's manufacturer is expanding their voluntary recalls. On Friday, Sanofi announced a recall of Zantac OTC in the U.S. and Canada. Teva Pharmaceutical and GlaxoSmithKline, among others, have also begun recalls for versions of the medicine.

CVS has said that customers who've purchased the products can return them for a refund and that “CVS Pharmacy will continue to sell other over-the-counter H2 blockers, including Pepcid, Tagamet and their respective generic equivalents, famotidine and cimetidine."

Discover AARP Members Only Access

Join AARP to Continue

Already a Member?

spinner image membership-card-w-shadow-192x134

Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP The Magazine.